MedTrace Logo

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00912964 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2030

Last updated 2024-11-21

Study results available
· View outcomes & findings →

Summary

The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.

Conditions

  • Urinary Bladder, Overactive

Interventions

DRUG

Mirabegron

Mirabegron tablets

DRUG

Placebo

Matching mirabegron placebo tablets.

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Use Central Contact · Astellas Pharma Europe B.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-28
Primary Completion
2010-04-27
Completion
2010-04-27

Countries

  • United States
  • Canada
  • Czechia
  • Denmark
  • Finland
  • Germany
  • Hungary
  • Norway
  • Slovakia
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00912964 on ClinicalTrials.gov